



ORIGINAL ARTICLE

Transbronchial lung cryobiopsy: Associated complications



R. Linhas^{a,*}, R. Marçôa^a, A. Oliveira^{a,b}, J. Almeida^{a,b}, S. Neves^{a,b,c}, S. Campinha^{a,b,c}

^a Department of Pulmonology, Centro Hospitalar Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal

^b Bronchoscopy Unit, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal

^c Interstitial Lung Diseases Unit, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal

Received 2 April 2017; accepted 9 July 2017

Available online 9 August 2017

KEYWORDS

Transbronchial lung cryobiopsy;
Interstitial lung disease;
Complications

Abstract

Introduction: Transbronchial lung cryobiopsy (TBC) has emerged as a diagnostic alternative to surgical lung biopsy in interstitial lung disease (ILD). Despite its less invasive nature, some associated complications have been described.

Objective: To evaluate complications of TBC and associated factors.

Methods: Prospective evaluation of all patients with ILD submitted to TBC in our centre. Clinicodemographic variables and factors associated to TBC complications were analyzed. The effect of the variables on the complication risk was evaluated by a logistic regression model.

Results: Ninety patients were included (mean age 60 ± 13 years; 58.9% male). Twenty-two patients presented pneumothorax, 18 (81.8%) of which were treated with chest tube drainage [median air leak time: 1 day (IQR = 2)]. Grade 2 and 3 bleeding was observed in 13 (14.4%) cases. Presence of visceral pleura in the sample accounted for almost more than 10 times the odds of pneumothorax (OR = 9.59, 95% CI 2.95–31.17, $p < 0.001$). Increased body mass index (BMI) was associated with bleeding (16% additional odds for each BMI unit increase (OR = 1.16, 95% CI 1.01–1.34, $p = 0.049$).

Conclusion: The most frequent complication of TBC was pneumothorax, although rapidly reversible. There was a positive association between pneumothorax and the presence of pleura in the biopsy samples as well as between bleeding and increased BMI. More studies about TBC complications are needed to improve the selection of the candidates for this procedure.

© 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: rita.linhas@gmail.com (R. Linhas).

Introduction

Interstitial lung disease (ILD) represents a heterogeneous group of diseases with different prognostic and therapeutic implications. The evaluation of patients with ILD is best achieved by a multidisciplinary approach combining clinical, radiologic, and pathologic features. In many circumstances a histological confirmation is required to establish the exact diagnosis.¹⁻⁵ Several techniques have evolved over the years and are employed in many centres. Conventional transbronchial lung biopsy (TLB) is not currently recommended in fibrotic lung disorders due to its low diagnostic yield⁶; besides, the procedure presents risks.⁷

Surgical lung biopsy (SLB) provides adequate lung specimens for histopathological analysis and is recommended as reference standard by current guidelines in ILD when a non-invasive diagnosis cannot confidently be made.^{6,8} However, it requires hospitalization and chest tube drainage and may be associated with significant morbidity (2–20%), including prolonged air leak and acute exacerbation as well as mortality (2–17%).⁹⁻¹² Moreover, many subjects are excluded because of increased risks of perioperative morbidity and mortality by a combination of advanced age, comorbidity, severe respiratory failure, and pulmonary hypertension.

Cryotherapy has been used in bronchoscopy since the sixties, mainly in the management of endobronchial lesions in patients with bronchial obstruction.¹³ More recently, transbronchial cryobiopsy (TBC) has been used for the assessment of ILD. The major advantage of TBC is that large pieces of tissue can be extracted with a higher percentage of alveolar tissue,¹⁴⁻¹⁸ fewer crush artefacts and less atelectasis.¹⁶⁻¹⁸ The greater volume of alveolar tissue correlates with a better diagnostic yield.¹⁵⁻¹⁹ Despite its less invasive nature, some associated complications have been described. The potential for bleeding and the pneumothorax rates up to 33%, often requiring inpatient admission and chest tube drainage, are the most commonly described.¹⁹⁻²³

We here investigate the safety of TBC in subjects with ILD and possible factors associated with its complications, in order to improve candidate selection for this procedure.

Methods

Study design

We conducted a prospective study of all patients with ILD undergoing TBC from May 2014 to December 2016 at the Bronchoscopy Unit of the Pulmonology Department of Vila Nova de Gaia/Espinho Hospital Centre. Medical records were analyzed and demographic data, chest high resolution computed tomographic (HRCT) scans, procedure and complications details and pathology were recorded. The indication for TBC was diffuse pulmonary infiltrates of unclear aetiology. The request for TBC was made by the pulmonologist dedicated to ILD. According to the standard of care protocol in our institution, patients were required to have a pO_2 of at least 60 mmHg under oxygen delivery up to 2liters/min, and normal blood count, electrolytes, markers of renal function and coagulation parameters. All anticoagulants were discontinued before the procedure as per guidelines.²⁴ Before the procedure, risks and possible

complications were explained to each patient and informed consent was obtained.

The procedure

All procedures were performed under general anaesthesia and by a pulmonologist experienced in interventional bronchoscopy. After intubation with a rigid tracheoscope (Storz 12mm[®]), a videobronchoscope was advanced to the desired segment (previously identified in the HRCT) and a flexible cryoprobe (2.4 mm, model 20416-032, Erbokryo[®] CA, Erbe, Germany) was passed through the videobronchoscope into the bronchial segment under fluoroscopic guidance. After confirming correct positioning (defined as having the tip of the probe perpendicular and about to 10 mm from the chest wall), a freezing time of 5 s was applied, time after which the bronchoscope and cryoprobe were removed as a single unit and a bronchial blocker balloon (Olympus[®] B5-2c), previously placed in the segment was inflated, in order to prevent haemorrhage. The frozen specimen was thawed in saline and fixed in formalin. Each patient had at least one biopsy using this technique. Only one lung was biopsied per patient and the number of biopsies taken depended upon the researcher.

In patients who had not previous had bronchoalveolar lavage, it was performed before cryobiopsy, usually in the most affected pulmonary lobe.

Complications

Severity of bleeding was classified as: grade 0 – no bleeding; grade 1 – estimated volume of aspirated blood <50 ml; grade 2 – estimated volume of aspirated blood of between 50 and 100 ml and requiring endoscopic procedures as instillation of topical adrenaline and/or ice-cold saline; grade 3 – estimated volume of aspirated blood >100 ml and requiring endoscopic procedures as instillation of topical adrenaline and/or ice-cold saline and/or haemostatic tamponade therapy; grade 4 – any life-threatening bleeding requiring transfusion or escalation of care such as admission to the intensive care unit or surgery consultation. To rule out pneumothorax, a chest X-ray was obtained within at least 2 h of the procedure.

Statistical analysis

Descriptive statistics were used to analyze patient characteristics. The categorical variables were reported in frequencies (n) and percentages (%). Continuous data were described as means and standard deviations (SD) when variables had symmetric distributions and as median and interquartile range (IQR) when variables had no symmetric distribution. Inferences were tested by the chi-squared test (qualitative variables), the t -test (normally distributed quantitative variables) or the Mann-Whitney U -test (nonnormally distributed quantitative variables). The effect of the significant variables that emerged from the previous analysis on bleeding and pneumothorax risk was evaluated by a multivariate logistic regression model. A p value of <0.05

was considered significant. Data was analyzed using SPSS software version 22.

Results

Patients and technique

We included 90 patients who underwent TBC. The procedure was performed mainly in ambulatory patients ($n=66$; 73.3%). Six patients (6.7%) were already hospitalized at our department, the majority of them with suspicious organizing pneumonia; 18 patients (20%) from other hospitals were previously admitted only for logistic reasons.

Baseline characteristics are represented in [Table 1](#).

Complications

The main complications of TBC were pneumothorax and bleeding, as presented in [Table 2](#). Pneumothorax was observed in 22 cases (22.4%), 18 of which (81.8% of total) required chest tube drainage. Median time of hospitalization was 1 day (IQR = 2). One patient presented a prolonged in-hospital stay (20 days) because of a persistent air leak. The risk of pneumothorax was increased when fragments of pleura were present in the biopsy sample ($p < 0.001$), but it did not correlate with number or size of specimens ($p = 0.607$, $p = 0.986$, respectively) ([Table 3](#)). A more detailed analysis was performed and we verified that in patients presenting fragments of pleura in the biopsy sample, the predicted DLCO% was lower in the group presenting pneumothorax (mean = 54.71, SD = 17.14) compared to the group without pneumothorax (mean = 64.84, SD = 18.62) (marginally significant, $p = 0.052$). Female patients presented a higher risk of pneumothorax ($p = 0.049$), but 88.9% of the female patients with pneumothorax presented visceral pleura in the biopsy samples ($p < 0.001$). Considering histology we verified that in our series the occurrence of pneumothorax was not higher in the group of patients presenting UIP/possible UIP pattern or fibrotic patterns, although these results were only marginally significant ($p = 0.062$ and $p = 0.086$, respectively) ([Table 3](#)). Despite the preventive use of a bronchial blocker balloon during TBC techniques, grade 2 and 3 bleeding was encountered in 13 (14.4%) cases, 8 (8.9%) grade 2 and 5 (5.6%) grade 3 ([Table 2](#)). As shown in [Table 4](#), there was a higher risk of grade 2 and 3 bleeding in patients presenting a higher BMI ($p = 0.022$) but there was no major risk of bleeding related to height ($p = 0.846$). We also addressed the issue of whether an increase in biopsies performed during each session of CBT and the mean size of the specimens raised the incidence of bleeding. There was no rise in the incidence of grade 2 and 3 bleeding when more cryobiopsies were performed in a session ($p = 0.003$), although it should be noted that if the patients started to bleed the biopsy was not repeated; the risk of major bleeding tended to be higher with the increasing mean size of the samples (marginally significant, $p = 0.054$) ([Table 4](#)). No patient required blood transfusion due to bleeding. Three patients (3.3%) required haemostatic tamponade therapy of a bronchial segment with oxidized regenerated cellulose due to bleeding, in the remaining patients no other measures beyond local treatment with cold saline or adrenaline was needed. All

Table 1 Patient characteristics.

Demographic data	
<i>Gender</i>	
Male [n (%)]	53 (58.9)
Female [n (%)]	47 (51.1)
<i>Age, years [mean (SD)]</i>	60 (13)
<i>Anthropometric parameters</i>	
BMI, kg/m ² [mean (SD)] ^a	29.23 (5.57)
Height, cm [mean (SD)] ^b	164 (10)
<i>Pulmonary function tests</i>	
FVC % of predicted [median (IQR)] ^c	85 (27)
DLCO % of predicted [mean (SD)] ^d	64 (18)
<i>PH [n (%)]^{e, f}</i>	8 (17.4)
<i>Clinical suspicion [n (%)]</i>	
OP	14 (15.6)
HP	14 (15.6)
NSIP	8 (8.9)
DIP	8 (8.9)
UIP	7 (7.8)
Drug toxicity	6 (6.7)
UIP/NSIP	5 (5.6)
UIP/HP	4 (4.4)
Sarcoidosis/silicosis	5 (5.6)
<i>HRCT lung patterns [n (%)]</i>	
Reticular pattern	18 (20)
Ground-glass opacification (GGO)	15 (16.7)
GGO + mosaic attenuation + interlobular septal thickening	11 (12.2)
Interlobular septal thickening in subpleural region + honeycombing	9 (10)
GGO + interlobular septal thickening	9 (10)
Traction bronchiectasis + reticulation in upper lobes	6 (6.7)
Other	22 (24.4)

BMI – body mass index; FVC – forced vital capacity; DLCO – diffusing capacity of the lung for carbon monoxide; PH – pulmonary hypertension; OP – organizing pneumonia; HP – hypersensitivity pneumonitis; NSIP – non-specific interstitial pneumonia; DIP – desquamative interstitial pneumonia; UIP – usual interstitial pneumonia

^a $n = 74$.

^b $n = 70$.

^c $n = 79$.

^d $n = 71$.

^e $n = 46$.

^f PH suggested by a SPAP ≥ 40 mmHg + pVc on echocardiography; only patients presenting values close to the limit and clinically stable were submitted to TBC.

Table 2 Adverse events.

<i>Pneumothorax total [n (%)]</i>	22 (22.4)
<i>Pneumothorax requiring drainage [n (%)]</i>	18 (20)
<i>Prolonged air leak^a [n (%)]</i>	1 (2)
<i>Days of drainage [median (IQR)]</i>	1 (2)
<i>Bleeding [n (%)]</i>	
Grade 2	8 (8.9)
Grade 3	5 (5.6)
Grade 4	0 (0)
<i>Transient respiratory failure [n (%)]</i>	2 (2.2)

^a Defined as an air leak persisting beyond the first week.²⁵

patients were discharged after bronchoscopy, and there was no recurrence of the haemoptysis. Considering pneumothorax and bleeding risk, a logistic regression analysis revealed that the presence of visceral pleura in the sample accounted for almost 10 times the odds of pneumothorax (OR = 9.59, 95% CI 2.95–31.17, $p < 0.001$). BMI accounted for 16% additional odds of bleeding for each BMI unit increase (OR = 1.16, 95% CI 1.01–1.34, $p = 0.049$). Two patients presented transient desaturation during the procedure with no need for interruption of the technique; both patients had a BMI over 30 kg/m². No other patients, besides the pneumothorax ones, needed hospitalization. We did not observe

Table 3 Risk factors for pneumothorax.

	Pneumothorax (n = 22; 22.4%)	No pneumothorax (n = 68; 75.6%)	p
<i>Gender [n (%)]</i>			
Male	9 (17)	44 (83)	0.049
Female	13 (35.1)	24 (64.9)	
<i>Age, years [mean (SD)]</i>	61 (15)	60 (12)	0.803
<i>BMC, kg/m² [median (IQR)]</i>	30.00 (5.42)	28.85 (7.66)	0.416
<i>Height, cm [mean (SD)]</i>	161 (12)	165 (9)	0.221
<i>FVC % of predicted [median (IQR)]</i>	78 (22)	88 (30)	0.129
<i>DLCO % of predicted [mean (SD)]</i>	61 (17)	65 (18)	0.333
<i>Number of bronchopulmonary segments undergoing biopsy [n (%)]</i>			
≥2 segments	5 (68.8)	11 (31.3)	0.527
1 segment	17 (23)	57 (77)	
<i>Number of fragments per patient [median (IQR)]</i>	4 (2)	4 (1)	0.607
<i>Number of lobes undergoing biopsy [n (%)]</i>			
≥2 lobes	3 (27.3)	8 (72.7)	1
1 lobe	19 (24.1)	60 (75.9)	
<i>Mean size of the specimens, mm [median (IQR)]</i>	4 (1.4)	4 (1)	0.986
<i>Size of all specimens per patient (sum of the major diameter of each sample), mm [mean (SD)]</i>	16 (5)	16 (5)	0.705
<i>Presence of visceral pleura in the sample [n (%)]</i>			
Yes	12 (60)	8 (40)	<0.001
No	10 (14.3)	60 (85.7)	
<i>Interlobular septal thickening + honeycombing + traction bronchiectasis in HRCT [n (%)]</i>			
Yes	2 (13.3)	13 (86.7)	0.343
No	20 (26.7)	55 (73.3)	
<i>UIP/possible UIP histology [n (%)]</i>			
Yes	1 (5.6)	17 (94.4)	0.062
No	21 (29.2)	51 (70.8)	
<i>ILD associated to tobacco [n (%)]^a</i>			
Yes	0 (0)	9 (100)	0.106
No	22 (27.2)	59 (72.8)	
<i>Fibrotic histology [n (%)]</i>			
Yes	2 (9.5)	19 (90.5)	0.086
No	20 (29)	49 (71)	

^a Smoking-related interstitial fibrosis (SRIF) + respiratory bronchiolitis interstitial lung disease (RB-ILD) + DIP + pulmonary langerhans cell histiocytosis (PLCH)

Table 4 Risk factors for bleeding.

	Grade 0 and 1 (n=77; 85.6%)	Grade 2 and 3 (n=13; 14.4%)	p
Gender [n (%)]			
Male	47 (88.7)	6 (11.3)	0.313
Female	30 (81.1)	7 (18.9)	
Age, years [mean (SD)]	60.27 (12.27)	58.03 (15.92)	0.561
BMI, kg/m² [median (IQR)]	29.0 (6.7)	34.5 (6.5)	0.022
Height, cm [mean (SD)]	164.06 (9.45)	160.75 (14.82)	0.846
PH [n (%)]			
No	33 (86.8)	5 (13.2)	0.999
Yes	7 (87.5)	1 (12.5)	
Number of bronchopulmonary segments undergoing biopsy [n (%)]			
≥2 segments	15 (93.8)	1 (6.3)	0.450
1 segment	62 (83.8)	12 (16.2)	
Number of bronchopulmonary segments per patient [median (IQR)]	1 (0)	1 (0)	0.299
Number of fragments per patient [median (IQR)]	4 (0)	3 (2)	0.003
Number of lobes undergoing biopsy [n (%)]			
≥2 lobes	10 (90.9)	1 (9.1)	0.999
1 lobe	67 (84.8)	12 (15.2)	
Size of the specimens, mm [median (IQR)]	4.0 (1.5)	4.75 (1.8)	0.054
Size of all specimens per patient (sum of the major diameter of each sample), mm [mean (SD)]	16.32 (5.21)	14.38 (6.83)	0.274

acute exacerbation of ILD, lung infection or mortality related to the procedure.

Discussion

Obtaining tissue from lung parenchyma is often crucial for diagnosis and treatment in many ILD. Over the last few years TBC has been implemented as a mean of obtaining histological samples in the diagnostic setting of ILD; it has been used as a quite new modality and carried in some institutions. Few studies have explored its safety issues. We have here analyzed the TBC complications and its associated risk factors.

Among the adverse events, pneumothorax represented the most important complication of TBC with an incidence of 22.4% (22 of 90 patients; chest tube drainage was required in 18 cases (20%). The incidence of pneumothorax described in previous studies varies. Some studies reported no episodes of pneumothorax^{14,26–30} while others reported pneumothorax rates of between 1.4% and 12% (comparable to regular forceps biopsies or even lower).^{15,31–34} In a retrospective analysis that included 297 ILD patients undergoing cryobiopsy pneumothorax was the most common complication occurring in 60 patients (20.2%), 46 cases (15.5%) requiring drainage.²¹ Another study showed the occurrence of pneumothorax in 33% (19/58) patients undergoing TBC, with the majority (15/19) requiring chest tube drainage and

hospitalization (average 6 days; range 1–9 days).²³ In these studies the procedure was taken under spontaneous breathing and the probe was cooled for approximately 5–6 s.

Hagmeyer et al. observed more pneumothorax events in patients submitted to jet ventilation (43%; 3/7) when compared to patients sedated and under spontaneous breathing over a bronchoscopy tube (12%; 3/25).²² In our study, all patients underwent general anaesthesia with jet ventilation; it could be a potential reason for the higher pneumothorax rate when compared to other studies that maintained spontaneous ventilation during the procedure. Also, the approximated time that the probe was cooled in our study was higher than the time used in other studies with lower adverse frequencies. Furthermore, all our patients were intubated and that could also have played a role in increasing the pneumothorax risk. In a study by Polletti and Hetzel the authors analyzed the experience of previous studies with patients intubated and not intubated. They verified that in the 'intubated group' the mean size of samples was higher and there were more complications than in the 'non-intubated group'.³⁵

In a recent interesting study by Bango-Álvarez et al., TBC was performed under spontaneous breathing, under moderate sedation and without fluoroscopy; the cryoprobe was moved forward distally until it was noted that it could not advance further and then retracted 1–2 cm. Using this technique they showed a low occurrence of pneumothorax (4.7%) and lack of pleura in all of the biopsies; which questions the

need for fluoroscopy.³⁴ On the other hand, we used fluoroscopy to guide the probe and defined a safe position as having its tip perpendicular and about 1 cm from the chest wall. Our study population was limited to ILD patients; in the majority of these patients it is necessary to take peripheral subpleural biopsies in order to obtain samples that adequately represent the histopathologic processes, possibly explaining the high pneumothorax incidence.

We found that the risk of pneumothorax increases when fragments of pleura are present in the biopsy, similar to previous reports.¹⁹ In the study by Ravaglia et al. the degree of fibrosis of the lower lung zones was significantly increased in patients with pneumothorax compared to those without pneumothorax; furthermore, the authors also found a significant correlation between the incidence of pneumothorax and the histological UIP pattern.²¹ In our study we found opposite findings; only one patient with pneumothorax presented UIP/possible UIP pattern and only two patients presented fibrotic histology (comparing to other possible patterns), although with only a marginally statistical significance. This could be explained by the presumable additional caution in the execution of the technique because of the major risk of events in those patients.

It also must be noted that only a proportion of the patients would require chest tube drainage with TBC, compared with 100% patients who undergo surgical lung biopsy. In our sample, the pneumothoraces requiring drainage rapidly resolved; the median drainage time was 1 day, which was lower than the drainage time described in the previously referred studies. This result is important as chest tubes inserted for a prolonged time could be associated with an increased rate of infection.³⁶

Although there is the potential for a large defect in the lung parenchyma following cryobiopsy, the occurrence of bleeding was low in our group (14.4%) and all cases were controlled only by local measures. In the majority of studies on this topic there were no episodes of severe bleeding needing blood transfusion or surgery and some studies did not report haemorrhage events^{15,30}; other studies showed the occurrence of bleeding in up to 56.4%.^{16,17,22,29,31,33} The systematic review in the study by Ravaglia et al. reported no severe bleeding even in studies not employing the Fogarty balloon and moderate bleeding was documented in 7 out of 12 studies; however, the definition of 'moderate' bleeding was vastly divergent between the studies.²¹

The low incidence of significant bleeding in our cohort could be explained partly due to the preventive use of a bronchial blocker balloon, which is inflated immediately while the bronchoscope is being withdrawn from the airway to remove the biopsy specimen from the cryoprobe. Moreover, the haemostatic effects of cooling by cryo could probably have contributed to diminishing the occurrence of that event. However, the preventive use of a bronchial blocker balloon in our study is considered a 'bias' in the interpretation of the results as it does not allow us to quantify the true incidence of bleeding complications.

We found a positive association between the risk of bleeding and BMI that could be explained by the higher restriction and collapse of the peripheral lung areas in heavy patients that make it difficult for the probe to advance more peripherally. Thus the biopsies are done in more central areas increasing the bleeding risk.

Exacerbations of the ILD after the cryobiopsy are rare as well as associated deaths^{19,21} which occur less than in surgical lung biopsy.^{9–11} In our cohort, we did not have any acute exacerbation.

One of the major limitations of our analysis was the sample size. Although the collection of the data was prospective some data were missing. We also were not able to evaluate the influence of the greater experience of the bronchoscopist on the risks of complications.

In conclusion, pneumothorax was the most frequent complication, occurring in about a quarter of cases, and the presence of pleura in the biopsy was associated with its increased risk. Increased BMI seemed to be a risk factor for increased bleeding. The present analysis highlights the relative safety of the TBC procedure comparing to other possible approaches. Despite the obvious tendency to an increase in the use of this technique in different centres, there is still a lack of standardization of the procedure, as well as lack of defined indications and contra-indications, which would be of key importance not only to increase the diagnostic yield but also to reduce the potential complications of this technique. Another important issue is the grading of complications like bleeding, since its definition also differs among centres. More studies about TBC complications are needed in order to improve candidate selection for this procedure.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Larsen BT, Colby TV. Update for pathologists on idiopathic interstitial pneumonias. *Arch Pathol Lab Med.* 2012;136:1234–41.
2. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. *Am J Respir Crit Care Med.* 2005;172:268–79.
3. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013;188:733–48.
4. Fishbein MC. Diagnosis: to biopsy or not to biopsy: assessing the role of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. *Chest.* 2005;128:520S–5S.
5. Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. *Eur Respir Rev.* 2013;22:158–62.
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic

- pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011;183:788–824.
7. Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. *Thorax.* 2013;68 Suppl. 1:i1–44.
 8. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Eur Respir J.* 2002;19:794–6.
 9. Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. *Eur Respir J.* 2001;17:175–9.
 10. Kreider ME, Hansen-Flaschen J, Ahmad NN, Rossman MD, Kaiser LR, Kucharczuk JC, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. *Ann Thorac Surg.* 2007;83:1140–4.
 11. Kondoh Y, Taniguchi H, Kitaichi M, Yokoi T, Johkoh T, Oishi T, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. *Respir Med.* 2006;100:1753–9.
 12. Ploones T, Osei-Agyemang T, Elze M, Palade E, Wagnetz D, Loop T, et al. Morbidity and mortality in patients with usual interstitial pneumonia (UIP) pattern undergoing surgery for lung biopsy. *Respir Med.* 2013;107:629–32.
 13. Vergnon JM, Huber RM, Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. *Eur Respir J.* 2006;28:200–18.
 14. Kropski JA, Pritchett JM, Mason WR, Sivarajan L, Gleaves LA, Johnson JE, et al. Bronchoscopic cryobiopsy for the diagnosis of diffuse parenchymal lung disease. *PLoS One.* 2013;8:e78674.
 15. Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. *Respiration.* 2009;78:203–8.
 16. Fruchter O, Fridel L, El Raouf BA, Abdel-Rahman N, Rosengarten D, Kramer MR. Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy. *Respirology.* 2014;19:683–8.
 17. Pajares V, Puzo C, Castillo D, Lerma E, Montero MA, Ramos-Barbón D, et al. Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: a randomized trial. *Respirology.* 2014;19:900–6.
 18. Griff S, Ammenwerth W, Schonfeld N, Bauer TT, Mairinger T, Blum TG, et al. Morphometrical analysis of transbronchial cryobiopsies. *Diagn Pathol.* 2011;6:53.
 19. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. *PLoS One.* 2014;9:e86716.
 20. Dhooria S, Sehgal IS, Aggarwal AN, Behera D, Agarwal R. Diagnostic yield and safety of cryoprobe transbronchial lung biopsy in diffuse parenchymal lung diseases: systematic review and meta-analysis. *Respir Care.* 2016;61:700–12.
 21. Ravaglia C, Bonifazi M, Wells AU, Tomassetti S, Gurioli C, Picciocchi S, et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. *Respiration.* 2016;91:215–27.
 22. Hagemeyer L, Theegarten D, Wohlschlagler J, Treml M, Matthes S, Priegnitz C, et al. The role of transbronchial cryobiopsy and surgical lung biopsy in the diagnostic algorithm of interstitial lung disease. *Clin Respir J.* 2016;10:589–95.
 23. Tomassetti S, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2016;193:745–52.
 24. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. *N Engl J Med.* 2013;368:2113–24.
 25. Periquet Y, Poncelet AJ. Persistent air leak (PAL): conservative vs. invasive approach? *Rev Mal Respir.* 2005;22:103–12.
 26. Fruchter O, Fridel L, Rosengarten D, Raviv Y, Rosanov V, Kramer MR. Transbronchial cryo-biopsy in lung transplantation patients: first report. *Respirology.* 2013;18:669–73.
 27. Fruchter O, Fridel L, Rosengarten D, Rahman NA, Kramer MR. Transbronchial cryobiopsy in immunocompromised patients with pulmonary infiltrates: a pilot study. *Lung.* 2013;191:619–24.
 28. Yarmus L, Akulian J, Gilbert C, Illei P, Shah P, Merlo C, et al. Cryoprobe transbronchial lung biopsy in patients after lung transplantation: a pilot safety study. *Chest.* 2013;143:621–6.
 29. Pajares V, Torrego A, Puzo C, Lerma E, Gil De Bernabe MA, et al. Transbronchial lung biopsy using cryoprobes. *Arch Bronconeumol.* 2010;46:111–5.
 30. Griff S, Schönfeld N, Ammenwerth W, Blum TG, Grah C, Bauer TT, et al. Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series. *BMC Pulm Med.* 2014;14:171.
 31. Ussavarungsi K, Kern RM, Roden AC, Ryu JH, Edell ES. Transbronchial cryobiopsy in diffuse parenchymal lung disease: retrospective analysis of 74 cases. *Chest.* 2017;151:400–8.
 32. Gershman E, Fruchter O, Benjamin F, Nader AR, Rosengarten D, Rusanov V, et al. Safety of cryo-transbronchial biopsy in diffuse lung diseases: analysis of three hundred cases. *Respiration.* 2015;90:40–6.
 33. Hernández-González F, Lucena CM, Ramírez J, Sánchez M, Jimenez MJ, Xaubet A, et al. Utilidad de la criobiopsia en el diagnóstico de la enfermedad pulmonar intersticial difusa: análisis de rentabilidad y coste. *Arch Bronconeumol.* 2015;51:261–7.
 34. Bango-Álvarez A, Ariza-Prota M, Torres-Rivas H, Fernández-Fernández L, Prieto A, Sánchez I, et al. Transbronchial cryobiopsy in interstitial lung disease: experience in 106 cases – how to do it. *ERJ Open Res.* 2017;3:00148–2016.
 35. Poletti V, Hetzel J. Transbronchial cryobiopsy in diffuse parenchymal lung disease: need for procedural standardization. *Respiration.* 2015;90:275–8.
 36. Chee CB, Abisheganaden J, Yeo JK, Lee P, Huan PY, Poh SC, et al. Persistent air-leak in spontaneous pneumothorax – clinical course and outcome. *Respir Med.* 1998;92:757–61.